An interventional study of EXCAP Exercise Program and 10-Hour Healthy Eating Timeframe (hEAT) in Breast Cancer and Cancer Related Fatigue, sponsored by University of Rochester. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by University of Rochester · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Breast Neoplasms by University of Rochester — 5 open to participants now, 5 under way, none of them phase 3. Breast Neoplasms · University of Rochester.
Among the 16 studies in Breast Neoplasms by University of Rochester, this one is the 10th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, and was the 14th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →5 of the 16 studies in Breast Neoplasms by University of Rochester are open now, in 1 country. Recruiting first, the newest first:
University of Rochester · Sites in United States
Ages 18–79 · Women only
University of Rochester · Sites in United States
Ages 18+
University of Rochester · Sites in United States
Ages 21+ · Women only · Healthy volunteers
University of Rochester · Sites in United States
Ages 65+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 34 across the 14 interventional studies, 150 across the 2 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Rochester is the lead sponsor of 729 studies on the registry; 116 are open to participants now.
Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.
3 of the studies in Breast Neoplasms by University of Rochester that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07599618University of RochesterEvaluation of a Patient-Centered Decision-Making Support Tool for Older Adults With Advanced Breast Cancer and Their Care Partners | 2027-07-01 |
| NCT03137095University of RochesterEffects of Chemotherapy on Cognitive Function in Breast Cancer Patients & Non-Cancer Control Subjects With Optional Sub-Study Research Brain MRI | 2027-07-31 |
| NCT07529353University of RochesterFeasibility of 'Exercise for CAncer Patients and Healthy EAting Timeframes' . | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Breast Neoplasms by University of Rochester, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the feasibility and preliminary effects of a home based exercise and activity program for individuals with cancer. Participants will engage in a structured intervention designed to support physical activity and symptom management. The study will assess changes in patient reported outcomes, functional measures, and overall adherence to the program. Findings will help determine whether this approach is practical and potentially beneficial for improving health related outcomes in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will complete a 6-week home-based combined lifestyle intervention consisting of a structured exercise program (EXCAP) and a self-selected 10-hour daily healthy eating timeframe. The intervention includes aerobic walking, progressive resistance band training, and daily tracking of eating timeframes and physical activity.
Behavioral: EXCAP Exercise Program · Behavioral: 10-Hour Healthy Eating Timeframe (hEAT)
Home-based walking prescription with progressive 5% weekly step increase and resistance band training performed at least twice per week over 6 weeks.
Participants will self-select and maintain a daily eating window of 10 hours or less for 6 weeks, with timing of first and last meals recorded daily.
Proportion of Participants Meeting Pre-Specified Adherence Criteria
Percentage of participants who meet all three adherence criteria during the 6-week intervention: Maintain a ≤10-hour eating timeframe on at least 50 percent of intervention days (21 of 42 days) Complete resistance band exercises at least 12 total sessions during the 6-week period Increase average weekly step count by at least 20 percent from baseline to Week 6
Time frame: Baseline to Day 42
Mean Change in Brief Fatigue Inventory Total Score
Mean difference in total BFI score from baseline (Day 0) to post-intervention (Day 42). Higher scores indicate greater fatigue.
Time frame: Baseline to Day 42
Mean Change in Multidimensional Fatigue Symptom Inventory Total Score
Mean difference in total MFSI score from baseline (Day 0) to post-intervention (Day 42). Higher scores indicate greater fatigue burden.
Time frame: Baseline to Day 42
Mean Change in Body Mass Index
Mean difference in BMI (kg/m²) measured at baseline and at Day 42.
Time frame: Baseline to Day 42
Mean Change in 30-Second Bicep Curl Test Repetitions
Mean difference in total number of completed bicep curl repetitions within 30 seconds from baseline to Day 42.
Time frame: Baseline to Day 42
Mean Change in 30-Second Chair Stand Test Repetitions
Mean difference in total number of completed chair stands within 30 seconds from baseline to Day 42.
Time frame: Baseline to Day 42
Mean Change in Estimated Submaximal VO2
Mean difference in estimated VO2submax (mL/kg/min) obtained from treadmill testing at baseline and Day 42.
Time frame: Baseline to Day 42
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 12 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.